HIV1/HIV2 Antibody Screen, 3rd Generation
Human immunodeficiency virus type 1 (HIV-1) has been identified as the primary cause of acquired immunodeficiency syndrome (AIDS). In 1986 human immunodeficiency virus type 2 (HIV-2) was isolated from an AIDS patients in West Africa. Both HIV-1 and HIV-2 are members of the genus Lentiviridae of the family of Retroviridae. The routes of transmission of HIV-1 and HIV-2 are the same; however, in HIV-2 infections the transmission and the viral replication rate are much lower. Although the parenteral transmission mode of HIV infection remains important, the most common mode of transmission is sexual. Viremia occurs in 4 to 11 days with RNA levels often in excess of 1,000,000 copies per mL. Seroconversion usually occurs within 2 to 6 weeks after exposure to infection, although it may occur earlier or much later in some cases.
The enhanced third-generation antigen sandwich assay for screening for HIV infection is a very sensitive and specific assay now in use for HIV screening. This assay detects antibody to HIV-1, HIV-2, and HIV-O (Group O) earlier than previous generations of tests. Sera which are repeatedly reactive in two out of three tests are subject to confirmatory testing by the western blot method or other confirmatory testing. Patients with indeterminate results should be retested 30 days later and again 2 to 5 months later if still indeterminate. For individuals who are confirmed positive for antibodies, appropriate counseling and medical evaluation should be offered.
Rapid HIV antibody tests are available and provide timely detection of antibody to HIV in cases of needle stick injury or exposure to potentially HIV-contaminated materials.
The CDC recommends that all pregnant women be offered HIV testing. Sensitivity and specificity of EIA assay is >99% after 8-12 weeks of infection. When combined with confirmatory tests, specificity is 99.995%.
- Screening for human immunodeficiency virus antibody type 1 and type 2
- Blood and tissue donor screening for human immunodeficiency virus antibody type 1 and type 2
- Follow up on those exposed with the initial negative testing (CDC recommendations) after 1, 3, 6, and 12 months
Positive in:
- HIV infection
- Small but significant number of (0.1 - 0.3%) yield false-positive results in EIA, which could be caused by the binding of low-affinity natural polyreactive antibodies; this requires a western blot method for confirmation
Negative in:
- Non-infected patients
- Infected patients with HIV 1/2, but the sample was collected before the antibody had time to develop
Positive results should be repeated in duplicate and are subject to confirmatory testing by the western blot (WB) method or other confirmatory testing. Patients with indeterminate results by WB should be retested 30 days later and again 2 to 5 months later if still indeterminate. For individuals who are confirmed positive for antibodies, appropriate counseling and medical evaluation should be offered.
Negative (Non-Reactive)
Serum (SST) or Plasma EDTA (Lavender), Citrate (Light Blue).
-
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Clin Virol. 2011 Dec;52 Suppl 1:S71-6. [PMID: 22005551]
- Clin Med. 2003 May-Jun;3(3):203-5. [PMID: 12848250]
- Infect Dis Clin North Am. 2000 Dec;14(4):791-808. [PMID: 11144639]
- J Clin Microbiol. 1998 Aug;36(8):2235-9. [PMID: 9665998]
- MLO Med Lab Obs. 2004;36:12. [PMID: 15318787]
- Contraception. 2004 Aug;70(2):141-7. [PMID: 15288219]
- Murray PR et al. (editors): Manual of Clinical Microbiology, 8th ed. ASM Press (2003).